Thomas John Charles
Known title: EVP, General CounselCIK: 0002114900
Associated companies
Transaction History
| KRYS | ▲ Buy | Option Exercise | 1,000 | $179K | 6/25/2026 | View on chart |
| KRYS | ▼ Sell | Open Market | 1,000 | $347K | 6/25/2026 | View on chart |
| KRYS | ▼ Sell | Open Market | 642 | $194K | 5/26/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Krystal Biotech: Analysts Question Durability of Rare-Disease Drug Moat
Recent analysis focuses on whether Krystal Biotech's rare-disease drug has a durable competitive advantage. This question is relevant as the stock trades near its 52-week high, with a trailing P/E of 39.5. The current price action shows a support rejection, indicating potential short-term volatility.
Krystal Biotech: Analysts Question Durability of Rare-Disease Drug Moat. Recent analysis focuses on whether Krystal Biotech's rare-disease drug has a durable competitive advantage. This question is relevant as the stock trades near its 52-week high, with a trailing P/E of 39.5. The current price action shows a support rejection, indicating potential short-term volatility.